All In Biotech

NDA 018604 · Bausch

Zovirax

Acyclovir · Topical · Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Sep 29, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Mar 29, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

396

92 Phase 3, 31 recruiting

FAERS reports

115,336

83,639 serious, 14,680 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 31, 2020.

INDICATIONS AND USAGE ZOVIRAX Ointment 5% is indicated in the management of initial genital herpes and in limited non-lifethreatening mucocutaneous HSV infections in immunocompromised patients.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 29, 1982 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • ZOVIRAX · ACYCLOVIR 5% · OINTMENT, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Acyclovir" as an intervention, any sponsor and status, largest first.

All 396 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue8,096
  • diarrhoea7,417
  • off label use6,407
  • pneumonia5,695
  • nausea5,651
  • pyrexia4,977
  • death4,923
  • drug ineffective4,759
  • rash4,308
  • dyspnoea3,608
  • asthenia3,360
  • headache3,298

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004879
20051,014
20061,020
20071,070
20081,327
20091,364
20101,424
20112,412
20122,446
20131,808
20142,467
20155,584
20165,828
20176,979
20188,210
20199,100
20209,880
202111,357
202210,637
20238,757
20248,201
20258,328
20265,242

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zovirax* (Acyclovir)

2024 spending

$170K

Beneficiaries

281

600 claims

Per beneficiary

$605

$28.57 per unit

View as table
YearSpending
2020$1,822,120
2021$584,006
2022$236,527
2023$178,514
2024$169,935

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 952 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.